Biotech | April 11, 2022
Lonza signs manufacturing deal with Asher Biotherapeutics
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Mahajan Imaging, which currently has 10 high-end medical diagnostic centres in Delhi-NCR and Jaipur, has ventured into a new field called Integrated Diagnostics
With close to 2,800 highly skilled employees, GITC is now one of the largest technology centres across the Life Sciences industry in the country
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
The hospital is committed to adding to specialised practices in the healthcare space with its pioneering effort to promote oral health awareness and tobacco addiction prevention
Although PCM has advanced substantially in recent years, most of the valuable technical information resides with private companies and academic publications across multiple platforms
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Subscribe To Our Newsletter & Stay Updated
